Clinical trials · Dallas–Fort Worth, TX
Locally Advanced clinical trials in Dallas–Fort Worth
We’re tracking 56 recruiting locally advanced studies with a site in or near Dallas–Fort Worth — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Dallas–Fort Worth
- NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Dallas, TexasAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Dallas, TexasAges 18–75 - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Dallas, TexasAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Dallas, TexasAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Dallas, TexasAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Dallas, TexasAges 18 years+ - NCT07196644RecruitingPhase 2
A study of a new drug for certain cancers with a specific gene change
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
Dallas, TexasAges 12 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Dallas, TexasAges 18 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Dallas, TexasAges Up to 25 years - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Dallas, TexasAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Dallas, TexasAges 18 years+ - NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
Dallas, TexasAges 18 years+ - NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Dallas, TexasAges 15 years+ - NCT06900595RecruitingPhase 2
Cabozantinib with immunotherapy for advanced adrenal cancer
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
Dallas, TexasAges 12 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Dallas, TexasAges 18–130 - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Dallas, TexasAges Any age - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Dallas, TexasAges 18 years+ - NCT03093116RecruitingPhase 1/Phase 2
Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Dallas, TexasAges 12 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
Dallas, TexasAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Dallas, TexasAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Irving, TexasAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Irving, TexasAges 18 years+ - NCT05458219RecruitingPhase 1
Testing an antibody-drug treatment for solid tumors
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
Irving, TexasAges 18 years+ - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Irving, TexasAges 18 years+
Hear when a new Locally Advanced trial opens near Dallas–Fort Worth, TX
We’ll email you when one opens near Dallas–Fort Worth, TX — at most once a week, no account needed, unsubscribe anytime.
Locally Advanced trials in other cities
Where these studies are running near Dallas–Fort Worth
Institutions with a site for the recruiting locally advanced studies listed above.
- Research Site · 4 studies
- University of Texas Southwestern Medical Center · 4 studies
- NEXT Oncology · 3 studies
- Mary Crowley Cancer Research · 2 studies
- Parkland Memorial Hospital · 2 studies
- UT Southwestern Medical Center · 2 studies
- Avenzo Therapeutics Recruiting Site
- Clinical Study Site
What taking part in a locally advanced study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting locally advanced studies in Texas.
Common questions
- Are there locally advanced clinical trials near Dallas–Fort Worth?
- Yes. We're currently tracking 56 recruiting locally advanced studies with a site near Dallas–Fort Worth, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a locally advanced study near Dallas–Fort Worth?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Dallas–Fort Worth to take part?
- Not necessarily. These studies have a site near Dallas–Fort Worth, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a locally advanced trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New locally advanced studies open near Dallas–Fort Worth regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.